Eliem Therapeutics agrees to acquire Tenet
Phase 1Acquisition
Preview
Source: Pharmaceutical Technology
The combined company will advance the clinical development of TNT119 for autoimmune diseases. Credit: Dragana Gordic / Shutterstock.com.
US-based Eliem Therapeutics has announced a definitive agreement for the acquisition of development-stage private biotechnology company Tenet Medicines.
The acquisition is aimed at enhancing Eliem’s portfolio with a clinical-stage programme targeting unmet needs in autoimmune diseases.
The deal is supported by a securities purchase agreement in which Eliem will sell 31,238,282 shares at $3.84 each, expecting to raise gross proceeds of $120m.
The private placement will see investments from investors including RA Capital Management, Boxer Capital, Deep Track Capital, Pontifax and Samsara Biocapital.
Following the acquisition and private placement, the cash reserves of the merged business will be $210m.
See Also:
Larimar Therapeutics gets grant for fusion protein for treating non-nuclear organelle associated disorders
Preview
Source: Pharmaceutical Technology
Aileron Therapeutics gets grant for modified CAV-1 peptides for lung infection and injury treatment
Preview
Source: Pharmaceutical Technology
This will support operations until 2027 and achieve significant milestones for TNT119, an anti-CD19 antibody.
TNT119 is being developed for autoimmune diseases including systemic lupus erythematosus and immune thrombocytopenia.
The merged company plans to advance the development of this asset.
The acquisition and private placement will conclude in the middle of 2024.
Tenet CEO Stephen Thomas stated: “Our team brings deep experience in immune disorders and on the heels of positive preliminary Phase I data for TNT119 in membranous nephropathy, we are excited to begin Phase II clinical development in systemic lupus erythematosus and immune thrombocytopenia.
“We believe that TNT119 has best-in-class potential and could be a transformative treatment option for many patients suffering from debilitating autoimmune disorders.
“This transaction and the support from leading life sciences investors will allow us to accelerate our development plans and continue advancing TNT119 for the potential benefit of patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.